Table 1 Patients' characteristics and... | American Society of Hematology

Table 1

Patients' characteristics and follow-up

Patient	Age (years)	Sex	Diagnosis	CBU TNC (×10⁷/kg)*		HLA match PD-CBU vs†		Status per May 2016			aGVHD
				CBU TNC (×10⁷/kg)*		Recipient class I/II	NE-CBU class I/II	Follow-up		Relapse
				CBU1	CBU2	Recipient class I/II	NE-CBU class I/II	Months	Alive	Relapse
1	56	Male	AML	3.6	2.1	4/5	3/5	90+	Yes	No	Yes
2	66	Female	foll NHL	3.2	4.3	3/3	6/3	43	No	No	No
3	31	Female	AML	1.8	1.6	2/2	6/5	83+	Yes	No	No
4	42	Female	CLL	3.9	2.8	4/2	5/3	2	No	No	Yes
5	65	Male	B-ALL	3.2	3.2	3/4	2/2	27+	Yes	No	Yes
6	53	Female	T-ALL	1.7	2.8	3/5	3/4	11	No	No	No
7	35	Male	CML	2.4	2.3	4/4	6/5	60+	Yes	No	Yes
8	39	Female	AA	3.4	1.9	4/1	3/2	7	No	No	Yes
9	54	Female	AML	2.6	5.1	6/2	6/0	11	No	No	Yes
10	46	Male	AML	2.9	2.3	5/3	5/5	54+	Yes	No	Yes
11	62	Male	AML	2.0	2.8	4/5	2/5	8	No	Yes	Yes
Median	53			2.9	2.8	4/3	5/4	43

Patient	Age (years)	Sex	Diagnosis	CBU TNC (×10⁷/kg)*		HLA match PD-CBU vs†		Status per May 2016			aGVHD
				CBU TNC (×10⁷/kg)*		Recipient class I/II	NE-CBU class I/II	Follow-up		Relapse
				CBU1	CBU2	Recipient class I/II	NE-CBU class I/II	Months	Alive	Relapse
1	56	Male	AML	3.6	2.1	4/5	3/5	90+	Yes	No	Yes
2	66	Female	foll NHL	3.2	4.3	3/3	6/3	43	No	No	No
3	31	Female	AML	1.8	1.6	2/2	6/5	83+	Yes	No	No
4	42	Female	CLL	3.9	2.8	4/2	5/3	2	No	No	Yes
5	65	Male	B-ALL	3.2	3.2	3/4	2/2	27+	Yes	No	Yes
6	53	Female	T-ALL	1.7	2.8	3/5	3/4	11	No	No	No
7	35	Male	CML	2.4	2.3	4/4	6/5	60+	Yes	No	Yes
8	39	Female	AA	3.4	1.9	4/1	3/2	7	No	No	Yes
9	54	Female	AML	2.6	5.1	6/2	6/0	11	No	No	Yes
10	46	Male	AML	2.9	2.3	5/3	5/5	54+	Yes	No	Yes
11	62	Male	AML	2.0	2.8	4/5	2/5	8	No	Yes	Yes
Median	53			2.9	2.8	4/3	5/4	43

Patients (except patients 1 and 6) were treated in the Hovon 106 study,⁷ with a preconditioning regimen of Flu/Cy/TBI 2x2Gy and all received graft-versus-host disease prophylaxe (cyclosporin A and mycophenolate mofetil). AA, aplastic anemia; AML, acute myeloid leukemia; aGVHD, acute graft-versus-host disease; B-ALL, acute B lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; Cy, cyclophosphamide; Flu, fludarabine; foll NHL, follicular non-Hodgkin lymphoma; T-ALL, acute T lymphoblastic leukemia; TBI, total body irradiation; TNC, total nucleated cell number.

Total nucleated cell count per kilogram recipient weight resulting from CBU1 and CBU2.

†

HLA match grade at HLA class I (HLA-A,-B,-C) allele level, maximum 6 (=6/6) and HLA class II (HLA-DRB1,-DQB1,-DPB1) allele level, maximum 6 (=6/6) between the PD-CBU and the recipient and between the PD-CBU and the NE-CBU.

View Large

This Feature Is Available To Subscribers Only